The role of COMT gene variants in depression: Bridging neuropsychological, behavioral and clinical phenotypes

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 8, 2013, Pages 1597-1610

  Antypa, Niki ^a,b   Drago, Antonio ^c   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b LEIDEN UNIVERSITY   (Netherlands)

^c IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Emotional processing; Endophenotype; Neuroimaging; Treatment response; Val158met polymorphism

Indexed keywords

ANTIDEPRESSANT AGENT; CATECHOL METHYLTRANSFERASE;

CATECHOL O METHYLTRANSFERASE GENE; DEPRESSION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG RESPONSE; ENDOPHENOTYPE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IMAGE ANALYSIS; LIMBIC CORTEX; MET GENE; MOLECULAR PATHOLOGY; NEUROIMAGING; PREDICTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEQUENCE ANALYSIS;

EMOTIONAL PROCESSING; ENDOPHENOTYPE; NEUROIMAGING; TREATMENT RESPONSE; VAL158MET POLYMORPHISM;

ALLELES; BRAIN; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER; EMOTIONS; GENETIC VARIATION; HUMANS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 84880141063     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.06.006     Document Type: Review

References (137)

1. Abdolmaleky H.M., Cheng K.H., Faraone S.V., Wilcox M., Glatt S.J., Gao F., Smith C.L., Shafa R., Aeali B., Carnevale J., Pan H., Papageorgis P., Ponte J.F., Sivaraman V., Tsuang M.T., Thiagalingam S. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum. Mol. Genet. 2006, 15:3132-3145.
2. Aberg E., Fandino-Losada A., Sjoholm L.K., Forsell Y., Lavebratt C. The functional Val158Met polymorphism in catechol-O-methyltransferase (COMT) is associated with depression and motivation in men from a Swedish population-based study. J. Affect. Disord. 2011, 129:158-166.
3. Arias B., Serretti A., Lorenzi C., Gasto C., Catalan R., Fananas L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J. Affect. Disord. 2006, 90:251-256.
4. Ashby F.G., Isen A.M., Turken A.U. A neuropsychological theory of positive affect and its influence on cognition. Psychol. Rev. 1999, 106:529-550.
5. Axelrod J., Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 1958, 233:702-705.
6. Baekken P.M., Skorpen F., Stordal E., Zwart J.A., Hagen K. Depression and anxiety in relation to catechol-O-methyltransferase Val158Met genotype in the general population: the Nord-Trondelag Health Study (HUNT). BMC Psychiat. 2008, 8:48.
7. Baghai T.C., Moller H.J. Electroconvulsive therapy and its different indications. Dialogues Clin. Neurosci. 2008, 10:105-117.
8. Baune B.T., Hohoff C., Berger K., Neumann A., Mortensen S., Roehrs T., Deckert J., Arolt V., Domschke K. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 2008, 33:924-932.
9. Benedetti F., Colombo C., Pirovano A., Marino E., Smeraldi E. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl) 2009, 203:155-160.
10. Benedetti F., Dallaspezia S., Colombo C., Lorenzi C., Pirovano A., Smeraldi E. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur. Psychiatry 2010, 25:476-478.
11. Bilder R.M., Volavka J., Lachman H.M., Grace A.A. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004, 29:1943-1961.
12. Blackburn J.R., Pfaus J.G., Phillips A.G. Dopamine functions in appetitive and defensive behaviours. Prog. Neurobiol. 1992, 39:247-279.
13. Bressan R.A., Costa D.C., Jones H.M., Ell P.J., Pilowsky L.S. Typical antipsychotic drugs-D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr. Res. 2002, 56:31-36.
14. Buckert M., Kudielka B.M., Reuter M., Fiebach C.J. The COMT Val158Met polymorphism modulates working memory performance under acute stress. Psychoneuroendocrinology 2012.
15. Bylsma L.M., Morris B.H., Rottenberg J. A meta-analysis of emotional reactivity in major depressive disorder. Clin. Psychol. Rev. 2008, 28:676-691.
16. Calati R., Porcelli S., Giegling I., Hartmann A.M., Moller H.J., De Ronchi D., Serretti A., Rujescu D. Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. J. Psychiatr. Res. 2011, 45:309-321.
17. Camara E., Kramer U.M., Cunillera T., Marco-Pallares J., Cucurell D., Nager W., Mestres-Misse A., Bauer P., Schule R., Schols L., Tempelmann C., Rodriguez-Fornells A., Munte T.F. The effects of COMT (Val108/158Met) and DRD4 (SNP -521) dopamine genotypes on brain activations related to valence and magnitude of rewards. Cereb. Cortex 2010, 20:1985-1996.
18. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 2004, 75:807-821.
19. Comasco E., Sylven S.M., Papadopoulos F.C., Sundstrom-Poromaa I., Oreland L., Skalkidou A. Postpartum depression symptoms: a case-control study on monoaminergic functional polymorphisms and environmental stressors. Psychiatr. Genet. 2011, 21:19-28.
20. Conway C.C., Hammen C., Brennan P.A., Lind P.A., Najman J.M. Interaction of chronic stress with serotonin transporter and catechol-O-methyltransferase polymorphisms in predicting youth depression. Depress. Anxiety 2010, 27:737-745.
21. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety 2000, 11:58-65.
22. Cusin C., Serretti A., Lattuada E., Lilli R., Lorenzi C., Smeraldi E. Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. Am. J. Med. Genet. 2002, 114:380-390.
23. Dannlowski U., Konrad C., Kugel H., Zwitserlood P., Domschke K., Schoning S., Ohrmann P., Bauer J., Pyka M., Hohoff C., Zhang W., Baune B.T., Heindel W., Arolt V., Suslow T. Emotion specific modulation of automatic amygdala responses by 5-HTTLPR genotype. Neuroimage 2009, 53:893-898.
24. Dannlowski U., Kugel H., Franke F., Stuhrmann A., Hohoff C., Zwanzger P., Lenzen T., Grotegerd D., Suslow T., Arolt V., Heindel W., Domschke K. Neuropeptide-S (NPS) receptor genotype modulates basolateral amygdala responsiveness to aversive stimuli. Neuropsychopharmacology 2011, 36:1879-1885.
25. Dannlowski U., Ohrmann P., Bauer J., Deckert J., Hohoff C., Kugel H., Arolt V., Heindel W., Kersting A., Baune B.T., Suslow T. 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression. Neuropsychopharmacology 2008, 33:418-424.
26. Dannlowski U., Ohrmann P., Bauer J., Kugel H., Baune B.T., Hohoff C., Kersting A., Arolt V., Heindel W., Deckert J., Suslow T. Serotonergic genes modulate amygdala activity in major depression. Genes Brain Behav. 2007, 6:672-676.
27. Dannlowski U., Ohrmann P., Konrad C., Domschke K., Bauer J., Kugel H., Hohoff C., Schoning S., Kersting A., Baune B.T., Mortensen L.S., Arolt V., Zwitserlood P., Deckert J., Heindel W., Suslow T. Reduced amygdala-prefrontal coupling in major depression: association with MAOA genotype and illness severity. Int. J. Neuropsychopharmacol. 2009, 12:11-22.
28. Domschke K., Baune B.T., Havlik L., Stuhrmann A., Suslow T., Kugel H., Zwanzger P., Grotegerd D., Sehlmeyer C., Arolt V., Dannlowski U. Catechol-O-methyltransferase gene variation: impact on amygdala response to aversive stimuli. Neuroimage 2012, 60:2222-2229.
29. Domschke K., Dannlowski U. Imaging genetics of anxiety disorders. Neuroimage 2010, 53:822-831.
30. Domschke K., Ohrmann P., Braun M., Suslow T., Bauer J., Hohoff C., Kersting A., Engelien A., Arolt V., Heindel W., Deckert J., Kugel H. Influence of the catechol-O-methyltransferase val158met genotype on amygdala and prefrontal cortex emotional processing in panic disorder. Psychiatry Res. 2008, 163:13-20.
31. Domschke K., Zavorotnyy M., Diemer J., Nitsche S., Hohoff C., Baune B.T., Deckert J., Arolt V., Zwanzger P. COMT val158met influence on electroconvulsive therapy response in major depression. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:286-290.
32. Doornbos B., Dijck-Brouwer D.A., Kema I.P., Tanke M.A., van Goor S.A., Muskiet F.A., Korf J. The development of peripartum depressive symptoms is associated with gene polymorphisms of MAOA, 5-HTT and COMT. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:1250-1254.
33. Drabant E.M., Hariri A.R., Meyer-Lindenberg A., Munoz K.E., Mattay V.S., Kolachana B.S., Egan M.F., Weinberger D.R. Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Arch. Gen. Psychiatry 2006, 63:1396-1406.
34. Drago A., Crisafulli C., Sidoti A., Serretti A. The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Prog. Neurobiol. 2011, 94:418-460.
35. Dreher J.C., Kohn P., Kolachana B., Weinberger D.R., Berman K.F. Variation in dopamine genes influences responsivity of the human reward system. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:617-622.
36. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct. 2008, 213:93-118.
37. Fijal B., Perlis R.H., Heinloth A.N., Houston J.P. The association of single nucleotide polymorphisms in the catechol-O-methyltransferase gene and pain scores in female patients with major depressive disorder. J. Pain 2010, 11:910-915. 915 e911-919.
38. Frisch A., Postilnick D., Rockah R., Michaelovsky E., Postilnick S., Birman E., Laor N., Rauchverger B., Kreinin A., Poyurovsky M., Schneidman M., Modai I., Weizman R. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Mol. Psychiatry 1999, 4:389-392.
39. Funke B., Malhotra A.K., Finn C.T., Plocik A.M., Lake S.L., Lencz T., DeRosse P., Kane J.M., Kucherlapati R. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav. Brain Funct. 2005, 1:19.
40. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9991-9996.
41. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
42. Groenewold N.A., Opmeer E.M., de Jonge P., Aleman A., Costafreda S.G. Emotional valence modulates brain functional abnormalities in depression: evidence from a meta-analysis of fMRI studies. Neurosci. Biobehav. Rev. 2012, 37:152-163.
43. Gudayol-Ferre E., Herrera-Guzman I., Camarena B., Cortes-Penagos C., Herrera-Abarca J.E., Martinez-Medina P., Cruz D., Hernandez S., Genis A., Carrillo-Guerrero M.Y., Aviles Reyes R., Guardia-Olmos J. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. J. Affect. Disord. 2010, 127:343-351.
44. Hansson E. Enzyme activities of monoamine oxidase, catechol-O-methyltransferase and gamma-aminobutyric acid transaminase in primary astroglial cultures and adult rat brain from different brain regions. Neurochem. Res. 1984, 9:45-57.
45. Harmer C.J., Goodwin G.M., Cowen P.J. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br. J. Psychiatry 2009, 195:102-108.
46. Harmer C.J., Shelley N.C., Cowen P.J., Goodwin G.M. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am. J. Psychiatry 2004, 161:1256-1263.
47. Harris E.C., Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br. J. Psychiatry 1997, 170:205-228.
48. Harrison P.J., Tunbridge E.M. Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology 2008, 33:3037-3045.
49. Hasler G., Northoff G. Discovering imaging endophenotypes for major depression. Mol. Psychiatry 2011, 16:604-619.
50. Henderson A.S., Korten A.E., Jorm A.F., Jacomb P.A., Christensen H., Rodgers B., Tan X., Easteal S. COMT and DRD3 polymorphisms, environmental exposures, and personality traits related to common mental disorders. Am. J. Med. Genet. 2000, 96:102-107.
51. Horvitz J.C. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience 2000, 96:651-656.
52. Houston J.P., Kohler J., Ostbye K.M., Heinloth A., Perlis R.H. Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder. Psychiatry Res. 2011, 189:475-477.
53. Huuhka K., Anttila S., Huuhka M., Hietala J., Huhtala H., Mononen N., Lehtimaki T., Leinonen E. Dopamine 2 receptor C957T and catechol-o-methyltransferase Val158Met polymorphisms are associated with treatment response in electroconvulsive therapy. Neurosci. Lett. 2008, 448:79-83.
54. Illi A., Setala-Soikkeli E., Kampman O., Viikki M., Nuolivirta T., Poutanen O., Huhtala H., Mononen N., Lehtimaki T., Leinonen E. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. Psychiatry Res. 2010, 176:85-87.
55. Jabbi M., Kema I.P., van der Pompe G., te Meerman G.J., Ormel J., den Boer J.A. Catechol-o-methyltransferase polymorphism and susceptibility to major depressive disorder modulates psychological stress response. Psychiatr. Genet. 2007, 17:183-193.
56. Jabbi M., Korf J., Kema I.P., Hartman C., van der Pompe G., Minderaa R.B., Ormel J., den Boer J.A. Convergent genetic modulation of the endocrine stress response involves polymorphic variations of 5-HTT, COMT and MAOA. Mol. Psychiatry 2007, 12:483-490.
57. Kaenmaki M., Tammimaki A., Myohanen T., Pakarinen K., Amberg C., Karayiorgou M., Gogos J.A., Mannisto P.T. Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J. Neurochem. 2010, 114:1745-1755.
58. Karhunen T., Tilgmann C., Ulmanen I., Julkunen I., Panula P. Distribution of catechol-O-methyltransferase enzyme in rat tissues. J. Histochem. Cytochem. 1994, 42:1079-1090.
59. Karoum F., Chrapusta S.J., Egan M.F. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J. Neurochem. 1994, 63:972-979.
60. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry 2010, 15:473-500.
61. Kempton M.J., Haldane M., Jogia J., Christodoulou T., Powell J., Collier D., Williams S.C., Frangou S. The effects of gender and COMT Val158Met polymorphism on fearful facial affect recognition: a fMRI study. Int. J. Neuropsychopharmacol. 2009, 12:371-381.
62. Kendler K.S., Karkowski L.M., Prescott C.A. Causal relationship between stressful life events and the onset of major depression. Am. J. Psychiatry 1999, 156:837-841.
63. Kienast T., Hariri A.R., Schlagenhauf F., Wrase J., Sterzer P., Buchholz H.G., Smolka M.N., Grunder G., Cumming P., Kumakura Y., Bartenstein P., Dolan R.J., Heinz A. Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat. Neurosci. 2008, 11:1381-1382.
64. Klauke B., Winter B., Gajewska A., Zwanzger P., Reif A., Herrmann M.J., Dlugos A., Warrings B., Jacob C., Muhlberger A., Arolt V., Pauli P., Deckert J., Domschke K. Affect-modulated startle: interactive influence of catechol-O-methyltransferase Val158Met genotype and childhood trauma. PLoS One 2012, 7:e39709.
65. Kocabas N.A., Faghel C., Barreto M., Kasper S., Linotte S., Mendlewicz J., Noro M., Oswald P., Souery D., Zohar J., Massat I. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. Int. Clin. Psychopharmacol. 2010, 25:218-227.
66. Kunugi H., Vallada H.P., Hoda F., Kirov G., Gill M., Aitchison K.J., Ball D., Arranz M.J., Murray R.M., Collier D.A. No evidence for an association of affective disorders with high- or low-activity allele of catechol-o-methyltransferase gene. Biol. Psychiatry 1997, 42:282-285.
67. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
68. Lai F.M., Spector S. Studies on the monoamine oxidase and catechol-O-methyltransferase of the rat cerebral microvessels. Arch. Int. Pharmacodyn. Ther. 1978, 233:227-234.
69. Langreth R., Waldholz M. New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist 1999, 4:426-427.
70. Lelli-Chiesa G., Kempton M.J., Jogia J., Tatarelli R., Girardi P., Powell J., Collier D.A., Frangou S. The impact of the Val158Met catechol-O-methyltransferase genotype on neural correlates of sad facial affect processing in patients with bipolar disorder and their relatives. Psychol. Med. 2011, 41:779-788.
71. Lin C.H., Lin K.S., Lin C.Y., Chen M.C., Lane H.Y. Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine. J. Clin. Psychiatry 2008, 69:54-59.
72. Lindvall M., Hardebo J.E., Owman C. Barrier mechanisms for neutrotransmitter monoamines in the choroid plexus. Acta Physiol. Scand. 1980, 108:215-221.
73. Lonsdorf T.B., Golkar A., Lindstom K.M., Fransson P., Schalling M., Ohman A., Ingvar M. 5-HTTLPR and COMTval158met genotype gate amygdala reactivity and habituation. Biol. Psychol. 2011, 87:106-112.
74. Mandelli L., Serretti A., Marino E., Pirovano A., Calati R., Colombo C. Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. Int. J. Neuropsychopharmacol. 2007, 10:437-447.
75. Massat I., Kocabas N.A., Crisafulli C., Chiesa A., Calati R., Linotte S., Kasper S., Fink M., Antonijevic I., Forray C., Snyder L., Bollen J., Zohar J., De Ronchi D., Souery D., Serretti A., Mendlewicz J. COMT and age at onset in mood disorders: a replication and extension study. Neurosci. Lett. 2011, 498:218-221.
76. Massat I., Souery D., Del-Favero J., Nothen M., Blackwood D., Muir W., Kaneva R., Serretti A., Lorenzi C., Rietschel M., Milanova V., Papadimitriou G.N., Dikeos D., Van Broekhoven C., Mendlewicz J. Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol. Psychiatry 2005, 10:598-605.
77. Mathews A., MacLeod C. Cognitive vulnerability to emotional disorders. Annu. Rev. Clin. Psychol. 2005, 1:167-195.
78. Matsumoto M., Weickert C.S., Akil M., Lipska B.K., Hyde T.M., Herman M.M., Kleinman J.E., Weinberger D.R. Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 2003, 116:127-137.
79. McGowan P.O., Kato T. Epigenetics in mood disorders. Environ. Health Prev. Med. 2008, 13:16-24.
80. Meyer-Lindenberg A. Imaging genetics of schizophrenia. Dialogues Clin. Neurosci. 2010, 12:449-456.
81. Meyer-Lindenberg A., Kohn P.D., Kolachana B., Kippenhan S., McInerney-Leo A., Nussbaum R., Weinberger D.R., Berman K.F. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat. Neurosci. 2005, 8:594-596.
82. Meyer-Lindenberg A., Weinberger D.R. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat. Rev. Neurosci. 2006, 7:818-827.
83. Mier D., Kirsch P., Meyer-Lindenberg A. Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. Mol. Psychiatry 2009, 15:918-927.
84. Milad M.R., Quirk G.J. Neurons in medial prefrontal cortex signal memory for fear extinction. Nature 2002, 420:70-74.
85. Montag C., Buckholtz J.W., Hartmann P., Merz M., Burk C., Hennig J., Reuter M. COMT genetic variation affects fear processing: psychophysiological evidence. Behav. Neurosci. 2008, 122:901-909.
86. Moreira R. The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clin. Drug Investig. 2011, 31(Suppl 1):5-17.
87. Murphy S.E., Norbury R., Godlewska B.R., Cowen P.J., Mannie Z.M., Harmer C.J., Munafo M.R. The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a meta-analysis. Mol. Psychiatry 2012.
88. Napolitano A., Cesura A.M., Da Prada M. The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. J. Neural Transm. Suppl. 1995, 45:35-45.
89. Naudts K.H., Azevedo R.T., David A.S., van Heeringen C., Gibbs A.A. Influence of COMT val158met and ADRA2B deletion polymorphisms on recollection and familiarity components of human emotional memory. J. Psychopharmacol. 2012, 26:819-829.
90. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol. 2002, 67:53-83.
91. Norbury R., Mackay C.E., Cowen P.J., Goodwin G.M., Harmer C.J. Short-term antidepressant treatment and facial processing. Functional magnetic resonance imaging study. Br. J. Psychiatry 2007, 190:531-532.
92. Ohara K., Nagai M., Suzuki Y. Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression. Neuroreport 1998, 9:1305-1308.
93. Opmeer E.M., Kortekaas R., Aleman A. Depression and the role of genes involved in dopamine metabolism and signalling. Prog. Neurobiol. 2010, 92:112-133.
94. Palmatier M.A., Kang A.M., Kidd K.K. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol. Psychiatry 1999, 46:557-567.
95. Pani L., Porcella A., Gessa G.L. The role of stress in the pathophysiology of the dopaminergic system. Mol. Psychiatry 2000, 5:14-21.
96. Perlis R.H., Fijal B., Adams D.H., Sutton V.K., Trivedi M.H., Houston J.P. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol. Psychiatry 2009, 65:785-791.
97. Phillips M.L., Drevets W.C., Rauch S.L., Lane R. Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol. Psychiatry 2003, 54:515-528.
98. Porcelli S., Drago A., Fabbri C., Serretti A. Mechanisms of antidepressant action: an integrated dopaminergic perspective. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1532-1543.
99. Price J.L., Drevets W.C. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010, 35:192-216.
100. Price J.L., Drevets W.C. Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn. Sci. 2012, 16:61-71.
101. Qin S., Cousijn H., Rijpkema M., Luo J., Franke B., Hermans E.J., Fernandez G. The effect of moderate acute psychological stress on working memory-related neural activity is modulated by a genetic variation in catecholaminergic function in humans. Front. Integr. Neurosci. 2012, 6:16.
102. Rasch B., Spalek K., Buholzer S., Luechinger R., Boesiger P., de Quervain D.J., Papassotiropoulos A. Aversive stimuli lead to differential amygdala activation and connectivity patterns depending on catechol-O-methyltransferase Val158Met genotype. Neuroimage 2010, 52:1712-1719.
103. Rivett A.J., Francis A., Roth J.A. Distinct cellular localization of membrane-bound and soluble forms of catechol-O-methyltransferase in brain. J. Neurochem. 1983, 40:215-219.
104. Ruhe H.G., Mason N.S., Schene A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 2007, 12:331-359.
105. Scharinger C., Rabl U., Sitte H.H., Pezawas L. Imaging genetics of mood disorders. Neuroimage 2010, 53:810-821.
106. Schosser A., Calati R., Serretti A., Massat I., Kocabas N.A., Papageorgiou K., Linotte S., Mendlewicz J., Souery D., Zohar J., Juven-Wetzler A., Montgomery S., Kasper S. The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder-a European multicenter study. Eur. Neuropsychopharmacol. 2011, 22:259-266.
107. Schultz W. Predictive reward signal of dopamine neurons. J. Neurophysiol. 1998, 80:1-27.
108. Serretti A., Rotondo A., Lorenzi C., Smeraldi E., Cassano G.B. Catechol-O-methyltransferase gene variants in mood disorders in the Italian population. Psychiatr. Genet. 2006, 16:181-182.
109. Slifstein M., Kolachana B., Simpson E.H., Tabares P., Cheng B., Duvall M., Frankle W.G., Weinberger D.R., Laruelle M., Abi-Dargham A. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol. Psychiatry 2008, 13:821-827.
110. Smolka M.N., Buhler M., Schumann G., Klein S., Hu X.Z., Moayer M., Zimmer A., Wrase J., Flor H., Mann K., Braus D.F., Goldman D., Heinz A. Gene-gene effects on central processing of aversive stimuli. Mol. Psychiatry 2007, 12:307-317.
111. Smolka M.N., Schumann G., Wrase J., Grusser S.M., Flor H., Mann K., Braus D.F., Goldman D., Buchel C., Heinz A. Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J. Neurosci. 2005, 25:836-842.
112. Soeiro-de-Souza M.G., Bio D.S., David D.P., Rodrigues dos Santos D., Kerr D.S., Gattaz W.F., Machado-Vieira R., Moreno R.A. COMT Met (158) modulates facial emotion recognition in bipolar I disorder mood episodes. J. Affect. Disord. 2012, 136:370-376.
113. Spronk D., Arns M., Barnett K.J., Cooper N.J., Gordon E. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study. J. Affect. Disord. 2011, 128:41-48.
114. Sullivan P.F., Neale M.C., Kendler K.S. Genetic epidemiology of major depression: review and meta-analysis. Am. J. Psychiatry 2000, 157:1552-1562.
115. Sullivan R.M., Gratton A. Relationships between stress-induced increases in medial prefrontal cortical dopamine and plasma corticosterone levels in rats: role of cerebral laterality. Neuroscience 1998, 83:81-91.
116. Swart M., Bruggeman R., Laroi F., Alizadeh B.Z., Kema I., Kortekaas R., Wiersma D., Aleman A. COMT Val158Met polymorphism, verbalizing of emotion and activation of affective brain systems. Neuroimage 2011, 55:338-344.
117. Szegedi A., Rujescu D., Tadic A., Muller M.J., Kohnen R., Stassen H.H., Dahmen N. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005, 5:49-53.
118. Taylor Tavares J.V., Drevets W.C., Sahakian B.J. Cognition in mania and depression. Psychol. Med. 2003, 33:959-967.
119. Tost H., Alam T., Meyer-Lindenberg A. Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neurosci. Biobehav. Rev. 2010, 34:689-700.
120. Trainor B.C. Stress responses and the mesolimbic dopamine system: social contexts and sex differences. Horm. Behav. 2011, 60:457-469.
121. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
122. Tsai S.J., Gau Y.T., Hong C.J., Liou Y.J., Yu Y.W., Chen T.J. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J. Affect. Disord. 2009, 113:183-187.
123. Tunbridge E.M., Harrison P.J. Importance of the COMT gene for sex differences in brain function and predisposition to psychiatric disorders. Curr. Top. Behav. Neurosci. 2011, 8:119-140.
124. Uher R. The role of genetic variation in the causation of mental illness: an evolution-informed framework. Mol. Psychiatry 2009, 14:1072-1082.
125. Uher R., McGuffin P. The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression: 2009 update. Mol. Psychiatry 2010, 15:18-22.
126. Ursini G., Bollati V., Fazio L., Porcelli A., Iacovelli L., Catalani A., Sinibaldi L., Gelao B., Romano R., Rampino A., Taurisano P., Mancini M., Di Giorgio A., Popolizio T., Baccarelli A., De Blasi A., Blasi G., Bertolino A. Stress-related methylation of the catechol-O-methyltransferase Val 158 allele predicts human prefrontal cognition and activity. J. Neurosci. 2011, 31:6692-6698.
127. Verhoeff N.P., Christensen B.K., Hussey D., Lee M., Papatheodorou G., Kopala L., Rui Q., Zipursky R.B., Kapur S. Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacol. Biochem. Behav. 2003, 74:425-432.
128. Vialou V., Feng J., Robison A.J., Nestler E.J. Epigenetic mechanisms of depression and antidepressant action. Annu. Rev. Pharmacol. Toxicol. 2013, 53:59-87.
129. Weiss E.M., Stadelmann E., Kohler C.G., Brensinger C.M., Nolan K.A., Oberacher H., Parson W., Pitterl F., Niederstatter H., Kemmler G., Hinterhuber H., Marksteiner J. Differential effect of catechol-O-methyltransferase Val158Met genotype on emotional recognition abilities in healthy men and women. J. Int. Neuropsychol. Soc. 2007, 13:881-887.
130. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995, 376:572-575.
131. Williams L.M., Gatt J.M., Grieve S.M., Dobson-Stone C., Paul R.H., Gordon E., Schofield P.R. COMT Val(108/158)Met polymorphism effects on emotional brain function and negativity bias. Neuroimage 2010, 53:918-925.
132. Wise R.A. Catecholamine theories of reward: a critical review. Brain Res. 1978, 152:215-247.
133. Wray N.R., James M.R., Dumenil T., Handoko H.Y., Lind P.A., Montgomery G.W., Martin N.G. Association study of candidate variants of COMT with neuroticism, anxiety and depression. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:1314-1318.
134. Xu Z., Zhang Z., Shi Y., Pu M., Yuan Y., Zhang X., Li L. Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response. J. Affect. Disord. 2011, 133:165-173.
135. Yacubian J., Sommer T., Schroeder K., Glascher J., Kalisch R., Leuenberger B., Braus D.F., Buchel C. Gene-gene interaction associated with neural reward sensitivity. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8125-8130.
136. Yoshida K., Higuchi H., Takahashi H., Kamata M., Sato K., Inoue K., Suzuki T., Itoh K., Ozaki N. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum. Psychopharmacol. 2008, 23:121-128.
137. Zalsman G., Huang Y.Y., Oquendo M.A., Brent D.A., Giner L., Haghighi F., Burke A.K., Ellis S.P., Currier D., Mann J.J. No association of COMT Val158Met polymorphism with suicidal behavior or CSF monoamine metabolites in mood disorders. Arch. Suicide Res. 2008, 12:327-335.